State Street Held 4.6% Of Vir Biotechnology Before Its Hepatitis Trial Results
The September-end position was passive, while Vir plans more hepatitis results and an FDA approval application in 2027.
State Street held 4.6% of Vir Biotechnology, which develops investigational medicines for infectious diseases, cancer and other serious conditions, at September's end—before its recent hepatitis-results rally. The institution reported the position in a passive ownership disclosure filed with the SEC Tuesday.
A September-End Holding, Not Control
State Street reported beneficial ownership of 7,822,781 common shares as of September 30. The position measures its holding at that date rather than during the drug developer's recent rally.
State Street certified that it bought and held the securities as part of ordinary business activity, rather than to change or influence Vir's control. It reported shared voting authority over 7,507,527 shares.
Hepatitis Results Put Vir In Focus
Vir's hepatitis delta treatment results helped take the stock to a nearly two-year high Monday. The company said its late-stage study combining elebsiran and tobevibart met all its goals; 79% of treated patients had undetectable virus after 48 weeks.
Smaller follow-up results also raised the possibility that patients could stop treatment without an immediate return of the virus. Those findings were preliminary, and concern a different question from suppressing the virus while patients receive treatment.
Vir's medicines remain candidates in development, rather than products approved for sale. Its business includes licensing technologies and bringing in candidates under collaboration agreements, as well as licensing selected candidates to other companies for further development and possible commercialization.
The company also uses dAIsY, its artificial-intelligence engine, to develop and engineer antibodies. Alongside elebsiran, its pipeline includes programs designed to engage T cells, and Vir has taken on regulatory sponsorship of all current trials for those programs.
More Hepatitis Data In 2027
Vir expects additional hepatitis results in the first quarter of 2027 and plans to seek FDA approval around midyear. Those remain planned steps, not an approval to sell the treatment.
Management expects its cash to support operations into late 2028. Vir had a market value of $2.3 billion in Tuesday trading as of 10:23 a.m. ET.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: VIR BIOTECHNOLOGY INC (VIR) — SEC EDGAR
- Is Vir Biotechnology (VIR) Overvalued After Its 127% Run? — Yahoo Finance
- VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets — Yahoo Finance
- Vir Stock Catapults To Nearly Two-Year High On Gilead-Rivaling Hepatitis D News | Investor's Business Daily — investors.com
- Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ) | Seeking Alpha — seekingalpha.com
- Is Vir Biotechnology (VIR) A Bargain After Its Hepatitis Delta Phase 3 Win? — Yahoo Finance